BioAtla/$BCAB
1D1W1MYTD1Y5YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
- Ticker
- $BCAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 41
- Headquarters
- San Diego, United States
- Website
- www.bioatla.com
BioAtla Metrics
BasicAdvanced
$5.2M
-
-$22.74
0.76
-
Price and volume
Market cap
$5.2M
Beta
0.76
52-week high
$6.52
52-week low
$2.81
Average daily volume
62K
Financial strength
Current ratio
0.203
Quick ratio
0.169
Long term debt to equity
-11.847
Total debt to equity
-16.18
Profitability
EBITDA (TTM)
-30.83
Gross margin (TTM)
-188.92%
Net profit margin (TTM)
-370.05%
Operating margin (TTM)
-365.00%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-105.86%
Return on equity (TTM)
118.74%
Valuation
Price to revenue (TTM)
0.511
Price to book
-0.14
Price to tangible book (TTM)
-0.14
Price to free cash flow (TTM)
-0.185
Free cash flow yield (TTM)
-540.54%
Free cash flow per share (TTM)
-16.972
Growth
Revenue change (TTM)
-22.73%
Earnings per share change (TTM)
-58.98%
3-year earnings per share growth (CAGR)
-44.39%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.